https://www.selleckchem.com/products/gm6001.html
The 35% w/v of C12-C16 fatty acid-based in situ forming matrix prolonged the VCM release over seven days in which C12, C14, C16 -based formulation reached 56, 84, and 85% cumulative drug release at 7th day. The release data fitted well with Higuchi's model. The developed formulations presented efficient antimicrobial activities against standard S. aureus, MRSA, Escherichia coli, and Candida albicans. Hence, VCM-loaded antisolvent-induced fatty acid-based in situ forming matrix is a potential local delivery system for the treatment of loc
Like
Comment
Share
